Phlexglobal
has launched its enhanced Resourcing Solutions division to offer increased flexibility for both commercial and NHS clients.
Following an internal restructure, Phlexglobal’s Resourcing Solutions division now comprises four subdivisions covering Recruitment, Insourced Services, Task Force and Clinical Support Services.
Resourcing Solutions is being led by Sarah Tucker who previously ran the company’s Task Force. Sarah commented: “Bringing together the four Resourcing Solutions enables Phlexglobal to support its clients through the provision of staff in the most flexible way. We offer a variety of costing and contractual models to our clients, to suit their current needs and constraints.”
The Recruitment subdivision focuses on permanent Clinical Trial Administrator (CTA), Document Manager, Clinical Research Associate (CRA), Project Manager and Research Nurse provision and Insourced Services provides these staff on a contract basis while still retaining all management. The Task Force team offers short term provision of highly experienced staff at a moment’s notice, to help with peaks in workload and to cover absence and longer term support comes from Clinical Support Services, either at Phlexglobal’s offices, at the client site or a combination of the two. Functional service provision of clinical trial administration will continue to be an essential part of this offering.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.